

inhibits T_{ck} cell-induced release of one or more pro-inflammatory cytokines from monocytes. Advantageously, the compound inhibits NF- κ B and conveniently activates PI3 kinase. A method of identifying a compound with efficacy in the treatment of a chronic inflammatory disease is also disclosed and includes the step of testing the compound for an ability to selectively inhibit T_{ck} cells. Preferably, this method of identifying a compound with efficacy in the treatment of a chronic inflammatory disease includes the step of testing the compound for an ability to selectively inhibit T_{ck} cell-induced release of one or more pro-inflammatory cytokines from monocytes. Conveniently, the pro-inflammatory cytokine is tumour necrosis factor α (TNF α). The disclosure further provides compounds identifiable or identified by the methods and the use of the compounds in medicine. Additionally, an antibody-like molecule with specificity for T_{ck} cells, and compounds comprising the antibody-like molecule and a cytotoxic moiety is disclosed.

IN THE CLAIMS

Please cancel the original slate including claims 1-55 without prejudice or disclaimer of any subject matter therein and substitute the following slate containing claims 56-114 for them as follows:

56(New). A method of treatment of a chronic inflammatory disease in a patient, the method comprising the administration